





















Filed • Approved


 antibody  protein  small molecule

As of Sep. 30, 2018




Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	NDA in preparation in CN	Kirin-Amgen	
				Renal Anemia	Filed in ID		
Oncology		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Mycosis Fungoides and Sézary Syndrome	Approved in US	In-House	POTELLIGENT®
				Cutaneous T-cell Lymphoma	Filed in EU		Additional Indication, Dosage and Administration
					Approved in JP		
Immunology/A llergy		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis	Filed in KR	Kirin-Amgen	
					Approved in TH		
					Filed in SG		
					Filed in MY		
					Filed in HK		
Central Nervous System		KW-6002 Istradefylline Oral	Adenosine A _{2A} Receptor Antagonist	Parkinson's Disease	NDA in preparation in US	In-House	
Other		©KRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH)	Filed in CA	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
					AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia

Phase II, Phase III








Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks	
Nephrology		©RTA 402 Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	Diabetic Kidney Disease	Phase III in JP	Licensed from Reata		
		KHK7580 Evocalcet Oral	Calcium Receptor Agonist	Hypercalcemia In Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism	Phase III in JP	Licensed from Mitsubishi Tanabe Pharma		
Oncology		©KHK2375 Entinostat Oral	HDAC Inhibitor	Breast Cancer	Phase II in JP	Syndax		
			KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma	Phase II in US, EU and others	In-House	POTELLIGENT®
Immunology/A llergy		©KHK4083 Injection	Anti-OX40 Fully Human Antibody	Ulcerative Colitis	Phase II in US, EU and others	In-House	POTELLIGENT® Human Antibody-Producing Technology	
			KHK4563 Benralizumab Injection	Anti-IL-5 Receptor Humanized Antibody	Chronic Obstructive Pulmonary Disease (COPD)	Phase III in JP	In-House	POTELLIGENT® Jointly Developed with AstraZeneca/MedImmune
					Eosinophilic Chronic Rhinosinusitis (ECRS)	Phase II in JP		
			KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Axial Spondyloarthritis (axSpA)	Phase III in JP, KR and TW	Kirin-Amgen	
	©ASKP1240 Bleselumab Injection	Anti-CD40 Fully Human Antibody	Recurrence of Focal Segmental Glomerulosclerosis (FSGS) in <i>de novo</i> kidney transplant recipients	Phase II in US	In-House	Human Antibody-Producing Technology Jointly Developed with Astellas		
Central Nervous System		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	HTLV-1 associated myelopathy (HAM)	Phase III in JP	In-House	POTELLIGENT®	
					©KW-6356 Oral	Adenosine A _{2A} Receptor Antagonist	Parkinson's Disease	Phase II in JP
Other		©KRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH) in adult patients	Phase III in US, CA, EU, JP and KR	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU	
				X-linked Hypophosphatemia (XLH) in pediatric patients	Phase III in US, CA, EU, AU, JP and KR			
				Tumor Induced Osteomalacia(TIO)/Epidermal Nevus Syndrome (ENS)	Phase II in US Phase II in JP and KR			
		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia	Phase II / III in KR	Kirin-Amgen		
Idiopathic (Immune) Thrombocytopenic Purpura				Phase III in CN				



 Updated since Jun. 30, 2018 (Area, Stage, Filed, Approved, etc.)
© New Molecular Entity

Ph I

 antibody
  protein
  small molecule




As of Sep. 30, 2018

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		ⓄKHK2455 Oral	IDO 1 Inhibitor	Solid Tumor	Phase I in US	In-House	Combination with KW-0761
		ⓄKHK2823 Injection	Anti-CD123 Fully Human Antibody	Cancer	Phase I in UK	In-House	POTELLIGENT® Human Antibody-Producing Technology
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Solid Tumor	Phase I / II in US	In-House	POTELLIGENT® Combination with Nivolumab (Jointly Developed with Bristol-Myers Squibb)
Immunology/ Allergy		ⓄKHK4083 Injection	Anti-OX40 Fully Human Antibody	Ulcerative Colitis Atopic Dermatitis	Phase I in JP Phase I in JP	In-House	POTELLIGENT® Human Antibody-Producing Technology
		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Autoimmune Disease	Phase I in JP	Kirin-Amgen	
Central Nervous System		ⓄKHK6640 Injection	Anti-Amyloid Beta Peptide Antibody	Alzheimer's Disease	Phase I in EU Phase I in JP	Licensed from Immunas Pharma	
Others		KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Phase I in EU	In-House	


 Updated since Jun. 30, 2018 (Area, Stage, Filed, Approved, etc.)
 New Molecular Entity

Updated since Jun. 30, 2018 (Area, Stage, Filed, Approved, etc.)

Filed • Approved

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Mycosis Fungoides and Sézary Syndrome	Approved in US	In-House	POTELLIGENT® Additional Indication, Dosage and Administration
	Cutaneous T-cell Lymphoma			Approved in JP			
Immunology/A llergy		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis	Filed in KR Approved in TH	Kirin-Amgen	
Other		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia	Filed in JP	Kirin-Amgen	

Terminated

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Solid Tumor	Phase I in JP	In-House	POTELLIGENT® Combination with Nivolumab (Jointly Developed with Ono Pharmaceutical)